Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 17Carcinoma, Hepatocellular 8Nasopharyngeal Carcinoma 7Recurrence 6Neoplasms 6Esophageal Neoplasms 6Breast Neoplasms 6Stomach Neoplasms 5Neoplasm Metastasis 5Esophageal Squamous Cell Carcinoma 5Colorectal Neoplasms 5Locally Advanced Rectal Cancer 4Carcinoma, Renal Cell 4Urinary Bladder Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma 3Rectal Neoplasms 3Melanoma 3Head and Neck Neoplasms 3Colonic Neoplasms 3Cholangiocarcinoma 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Leukemia, Myeloid, Acute 2Hyperthermia 2Chondrosarcoma 2Carcinoma, Transitional Cell 2

Interventions

Pemetrexed 4pembrolizumab 3Ramucirumab 2Gemcitabine 2Carboplatin 2vistusertib 1vandetanib 1tusamitamab ravtansine 1telomerase reverse transcriptase p572Y, human 1sintilimab 1olaparib 1necitumumab 1icotinib 1durvalumab 1dacomitinib 1capivasertib 1Vinorelbine 1LY3023414 1Injections 1Immune Checkpoint Inhibitors 1Erlotinib Hydrochloride 1Drug Therapy 1Docetaxel 1Cisplatin 1Bevacizumab 1AZD4547 1AZD 8931 1AZD 6244 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Non-small Cell Lung Cancer Metastatic × Immune Checkpoint Inhibitors × Clear all
NCT04836728 2025-03-13

CCICC-002b

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Active not recruiting
156 enrolled
Thoracic

Non-small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡